T1	Drug 18 21	HES
T2	Drug 23 41	dextrane solutions
T3	Multiplier 45 53	> 500 ml
T4	Drug 57 74	Gelatin solutions
T5	Temporal 75 113	within the 24 h prior to randomization
*	OR T1 T2 T4
R1	Has_multiplier Arg1:T4 Arg2:T3	
T6	Scope 18 74	HES, dextrane solutions or > 500 ml of Gelatin solutions
R2	Has_temporal Arg1:T6 Arg2:T5	
T7	Observation 115 129	Death expected
T8	Temporal 130 150	within the next 48 h
R3	Has_temporal Arg1:T7 Arg2:T8	
T9	Condition 152 160	moribund
T10	Measurement 184 187	ASA
T11	Value 188 197	= class V
R4	Has_value Arg1:T10 Arg2:T11	
R5	Subsumes Arg1:T9 Arg2:T10	
R6	Subsumes Arg1:T7 Arg2:T9	
T12	Non-query-able 200 264	Patients whose medical condition does preclude the PLR manoeuvre
T13	Non-representable 266 327	Patients for whom the need of pressure infusions are expected
T14	Condition 345 358	renal support
T15	Mood 329 344	Requirement for
R7	Has_mood Arg1:T14 Arg2:T15	
T16	Drug 517 524	heparin
T17	Condition 543 570	chronic coagulation disease
T18	Drug 573 599	anticoagulation medication
T19	Measurement 606 633	partial thromboplastin time
T20	Value 634 642	> 60 sec
R9	Has_value Arg1:T19 Arg2:T20	
*	OR T17 T18
T21	Scope 543 599	chronic coagulation disease / anticoagulation medication
R8	Has_scope Arg1:T16 Arg2:T21	
T22	Condition 645 659	Acutely burned
T23	Non-representable 670 781	Contraindications according to summary of product characteristics of investigational test and reference product
T24	Non-query-able 783 885	Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
